Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

Clinical Infectious Diseases

Volumn 26, Issue 5, 1998, Pages 1104-1106

  Zylberberg, Hervé ^a   Chaix, Marie Laure ^b   Rabian, Cécile ^b   Rouzioux, Christine ^b   Aulong, Bertrand ^b   Bréchot, Christian ^b   Viard, Jean Paul ^b   Pol, Stanislas ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HEPATITIS C ANTIBODY; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SUPERINFECTION; VIRUS REPLICATION;

EID: 0031948259     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520281     Document Type: Article

References (12)

1. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet 1996;348:800-3.
2. Gerber MA. Pathobiologic effects of hepatitis C. J Hepatol 1995;22(suppl 1):S83-6.
3. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011-7.
4. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-81.
5. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-3.
6. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
7. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997;336:919-22.
8. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-25.
9. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997;63:158-60.
10. + lymphocyte responses to antiretroviral therapy of HIV infection. J Acqu Immune Defic Syndr Hum Retrovirol 1996;13:320-6.
11. Gilkin J, Piketty C, Thomas V, Gonzales-Canali G, Kazatchkine MD. Acute CMV infection in AIDS patients receiving combination therapy including protease inhibitors [abstract no 354]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections. Washington, DC: American Society for Microbiology, 1996.
12. Bräu N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-5.